Business Context and Reporting Period
Company: Abeona Therapeutics Inc. (ABEO)
Filing Type: Form 8-K (Current Report)
Date of Report: July 5, 2024
Reporting Period: Specific event date of July 5, 2024, with bylaw amendments effective July 8, 2024.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a corporate governance report.
Material Changes
The Board of Directors approved an amendment and restatement of the Company's Bylaws (the "Second A&R Bylaws"). The primary change modifies the notice requirement for special meetings of the Board of Directors:
- Special meetings may now be called with not less than 24 hours' notice.
- Notice may be delivered personally, by telephone, electronic mail, or other electronic transmission.
- The amendment became effective on July 8, 2024.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, risk factors, contingencies, or discussion of unusual items. It is strictly limited to the procedural amendment of corporate bylaws.
Key Facts for Investor Verification
- Verify the full text of the Second A&R Bylaws filed as Exhibit 3.1 to this 8-K.
- Confirm the effective date of the bylaw amendment is July 8, 2024.
- Note that this filing does not impact the Company's financial position or operational results.